XRP has fallen about 7% this week, trading near a critical support level of $1.15 after failing to hold gains above $1.35 earlier. The cryptocurrency faces bearish technical signals and could drop further to $1.10 if it breaks below $1.15. Institutional interest via spot XRP ETFs has stalled, showing no new inflows despite $1.81 billion in historical demand. Investors are closely watching the upcoming U.S. inflation report on November 10, which could influence Federal Reserve policy and impact XRP's price direction.
XRP's price is currently testing the $1.15 support level amid a recent 7% weekly decline. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 09, 2026 01:02 WIB: out of 50 major cryptocurrencies priced on Pluang, 8 rose and 40 fell today. Notable movers include EGLD at Rp53.931 with a 1-day change of -5.11% and 100% buy order activity, FIL at Rp13.839 down 4.75% with 84% sell orders, and XTZ at Rp4.567 down 4.32% with 90% sell orders.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
BJ's Wholesale Club Holdings continues to grow in revenue, club count, and comparable sales, maintaining a positive outlook despite slight underperformance against the S&P 500. The company trades at attractive valuations compared to peers, with impro...
